These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 362814)

  • 21. [Studies on the significance of middle molecular retention products as uremia toxins].
    Goubeaud G; Leber HW; Schott HH
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1244-6. PubMed ID: 611827
    [No Abstract]   [Full Text] [Related]  

  • 22. [Study of middle molecular weight fraction in the plasma of patients with uremia using high performance liquid chromatography and thin layer chromatography].
    Kovalishin IaF; Nikolaev VG; Baran EIa; Dudar' IA; Iushko LA
    Vopr Med Khim; 1988; 34(6):23-6. PubMed ID: 3238937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of phenylbutazone and chloramphenicol on phagocytosis of radiolabelled Candida albicans by human monocytes cultured in vitro.
    Odegaard A; Lamvik J
    Acta Pathol Microbiol Scand C; 1976 Feb; 84(1):37-44. PubMed ID: 773098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of uremic "middle molecular" fractions by gas chromatography, mass spectrometry, isotachophoresis, and liquid chromatography.
    Schoots AC; Mikkers FE; Claessens HA; De Smet R; Van Landschoot N; Ringoir SM
    Clin Chem; 1982 Jan; 28(1):45-9. PubMed ID: 7055936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non diffusible toxic polypeptides in uraemic sera: a new group of uraemic toxins.
    Gróf J; Menyhárt J
    Acta Chir Acad Sci Hung; 1977; 18(3):283-7. PubMed ID: 605725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. II. Chief peptide constituents of the faction.
    Klein A; Sarnecka-Keller M; Hanicki Z
    Clin Chim Acta; 1978 Nov; 90(1):7-11. PubMed ID: 719891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scaling up in isolation of medium-size uraemic toxins.
    Gallice PM; Crevat AD; Berland YF
    J Chromatogr; 1991 Feb; 539(2):449-53. PubMed ID: 2045455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extraction of uraemic toxins with activated carbon restores the functional properties of albumin.
    Sarnatskaya VV; Lindup WE; Ivanov AI; Yushko LA; Tjia J; Maslenny VN; Gurina NM; Nikolaev VG
    Nephron Physiol; 2003; 95(1):p10-8. PubMed ID: 14520007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 31. Separation of six uremic middle molecular compounds by high performance liquid chromatography and analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu J; Yuan Z; Liu X; Wu Q; Mi H; He B
    Clin Chim Acta; 2001 Sep; 311(2):95-107. PubMed ID: 11566169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of uraemic "middle-sized molecules" on T lymphocyte functions.
    Kálmán K; Löcsey L; Hauck M; Leövey A
    Int Urol Nephrol; 1980; 12(4):367-74. PubMed ID: 6763010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical analytic approaches to the definition of uremic toxins.
    Furst P; Bergstrom J; Gordon A; Zimmermann L
    Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
    Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
    Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromatographic analysis of middle molecules in plasma ultrafiltrates of uraemic patients.
    Popławski A; Myśliwiec M
    Nephrol Dial Transplant; 1993; 8(2):188. PubMed ID: 8384345
    [No Abstract]   [Full Text] [Related]  

  • 37. Genesis of the uraemic syndrome: role of uraemic toxins.
    Hörl WH
    Wien Klin Wochenschr; 1998 Aug; 110(15):511-20. PubMed ID: 9782569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu.
    Steddon SJ; McIntyre CW; Schroeder NJ; Burrin JM; Cunningham J
    Nephrol Dial Transplant; 2004 Dec; 19(12):3078-83. PubMed ID: 15494357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins.
    Klammt S; Wojak HJ; Mitzner A; Koball S; Rychly J; Reisinger EC; Mitzner S
    Nephrol Dial Transplant; 2012 Jun; 27(6):2377-83. PubMed ID: 22086973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatomedin inhibitor in uremia.
    Phillips LS; Fusco AC; Unterman TG; del Greco F
    J Clin Endocrinol Metab; 1984 Oct; 59(4):764-72. PubMed ID: 6384255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.